Skip to content

Study · Not a test of the peptide alone · 2022

2 results

A retrospective, single-center cohort study on complications after dental extractions in patients taking biologic agents.

Davila A, Magee R, France K

Journal of the American Dental Association (1939)15 Sept 2022Cited by 2 (Europe PMC)

PMID36115715 (opens in a new tab)DOI10.1016/j.adaj.2022.07.009 (opens in a new tab)PepBankPUB-36115715
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome

    In dental extraction patients receiving several biologics, including dulaglutide, fifteen patients experienced complications in a pooled cohort.

    In plain wordsComplications occurred after dental extraction in a mixed biologic-treatment cohort that included dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicablePostextraction complications during biologic treatment
    Study

    n = 121

    Outcome group
    Adverse events · Whole body

    Measurements

    Patients with complications
    15 patients
    pooled biologic agents
    Encounters with complications
    16 encounters
    pooled biologic agents

    Source sentences

    Summary
    Fifteen patients experienced complications during 16 encounters.
    3 context sentences
    Summary · context
    Patients who experienced complications were treated with 7 biologic agents: dulaglutide, belimumab, adalimumab, aflibercept, tofacitinib, ranibizumab, and ixekizumab.
    Summary · context
    This retrospective case-control study analyzed patients undergoing dental extraction treated with biologic agents from 2017 through 2020.
    Summary · context
    Complications within 30 days postextraction were recorded.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome

    In a pooled biologic-treatment cohort including dulaglutide, notable or excessive pain was the most common dental extraction complication.

    In plain wordsPain was the most common dental extraction complication in a mixed biologic-treatment cohort that included dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNotable or excessive postextraction pain
    Study

    n: not reported in source

    Outcome group
    Pain · Whole body

    Measurements

    Pain encounters
    14 encounters
    16 complication encounters
    Pain proportion
    88%
    complication encounters

    Source sentences

    Summary
    Notable or excessive pain was most common (14/16; 88%).
    3 context sentences
    Summary · context
    Patients who experienced complications were treated with 7 biologic agents: dulaglutide, belimumab, adalimumab, aflibercept, tofacitinib, ranibizumab, and ixekizumab.
    Summary · context
    This retrospective case-control study analyzed patients undergoing dental extraction treated with biologic agents from 2017 through 2020.
    Summary · context
    Complications within 30 days postextraction were recorded.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.